OBJECTIVE: To examine racial differences in medication use by older long-stay Veterans Affairs Nursing Home Care Unit (NHCU) patients. DESIGN: Longitudinal study. SETTINGS: 133 Veterans Affairs NHCUs. PARTICIPANTS: Three thousand four hundred eighty veterans 65 years of age or older admitted between January 1, 2004, and June 30, 2005, for 90 days or more. MAIN OUTCOMES MEASURES: Prevalence of those taking nine or more medications (i.e., polypharmacy) and medications from specific therapeutic medication classes. Racial differences were determined using 0.05 level chi-squared tests. RESULTS: The sample consisted of 14.3% who were black. Blacks compared with whites (all comparisons P < 0.05 except where noted) were younger (13.6% vs. 17.4%, older than 85 years of age), had less depression (22.24 vs. 29.79%), less allergies (9.82% vs. 20.36%), and a similar rate of moderate-to severe pain (22.65% vs. 24.05; P = 0.49). The percent of polypharmacy was similar by race (blacks 74.35% vs. whites 71.18%; P = 0.62), as was the prevalence of medication class use with the exceptions that blacks were less likely than whites to take central nervous system (CNS) medications (75.75% vs. 80.14%; P = 0.02) and antihistamines (13.03% vs. 16.8%; P = 0.04). Specifically, blacks were less likely than whites to receive a selective serotonin-reuptake inhibitor (SSRI) antidepressant (20.84% vs. 27.17%; P < 0.01) or a second-generation antihistamine (3.41% vs. 6.51%; P < 0.01), but more likely than whites to receive opioids (14.63% vs. 11.27%; P = 0.03). CONCLUSION: There appears to be racial differences in the overall use of antihistamines and CNS medications and some of their subclasses.
OBJECTIVE: To examine racial differences in medication use by older long-stay Veterans Affairs Nursing Home Care Unit (NHCU) patients. DESIGN: Longitudinal study. SETTINGS: 133 Veterans Affairs NHCUs. PARTICIPANTS: Three thousand four hundred eighty veterans 65 years of age or older admitted between January 1, 2004, and June 30, 2005, for 90 days or more. MAIN OUTCOMES MEASURES: Prevalence of those taking nine or more medications (i.e., polypharmacy) and medications from specific therapeutic medication classes. Racial differences were determined using 0.05 level chi-squared tests. RESULTS: The sample consisted of 14.3% who were black. Blacks compared with whites (all comparisons P < 0.05 except where noted) were younger (13.6% vs. 17.4%, older than 85 years of age), had less depression (22.24 vs. 29.79%), less allergies (9.82% vs. 20.36%), and a similar rate of moderate-to severe pain (22.65% vs. 24.05; P = 0.49). The percent of polypharmacy was similar by race (blacks 74.35% vs. whites 71.18%; P = 0.62), as was the prevalence of medication class use with the exceptions that blacks were less likely than whites to take central nervous system (CNS) medications (75.75% vs. 80.14%; P = 0.02) and antihistamines (13.03% vs. 16.8%; P = 0.04). Specifically, blacks were less likely than whites to receive a selective serotonin-reuptake inhibitor (SSRI) antidepressant (20.84% vs. 27.17%; P < 0.01) or a second-generation antihistamine (3.41% vs. 6.51%; P < 0.01), but more likely than whites to receive opioids (14.63% vs. 11.27%; P = 0.03). CONCLUSION: There appears to be racial differences in the overall use of antihistamines and CNS medications and some of their subclasses.
Authors: Eleanor S McConnell; Carl F Pieper; Richard J Sloane; Laurence G Branch Journal: J Gerontol A Biol Sci Med Sci Date: 2002-12 Impact factor: 6.053
Authors: Somnath Saha; Michele Freeman; Joahd Toure; Kimberly M Tippens; Christine Weeks; Said Ibrahim Journal: J Gen Intern Med Date: 2008-02-27 Impact factor: 5.128
Authors: Aida B Won; Kate L Lapane; Sue Vallow; Jeff Schein; John N Morris; Lewis A Lipsitz Journal: J Am Geriatr Soc Date: 2004-06 Impact factor: 5.562
Authors: Joseph T Hanlon; Xiaoqiang Wang; Nicholas G Castle; Roslyn A Stone; Steven M Handler; Todd P Semla; Mary Jo Pugh; Dan R Berlowitz; Maurice W Dysken Journal: J Am Geriatr Soc Date: 2011-08-08 Impact factor: 5.562
Authors: Joseph T Hanlon; Sherrie L Aspinall; Steven M Handler; Walid F Gellad; Roslyn A Stone; Todd P Semla; Mary Jo V Pugh; Maurice W Dysken Journal: Ann Pharmacother Date: 2014-11-07 Impact factor: 3.154
Authors: Joseph T Hanlon; Xiaoqiang Wang; Steven M Handler; Steven Weisbord; Mary Jo Pugh; Todd Semla; Roslyn A Stone; Sherrie L Aspinall Journal: J Am Med Dir Assoc Date: 2010-10-02 Impact factor: 4.669
Authors: Walid F Gellad; Sherrie L Aspinall; Steven M Handler; Roslyn A Stone; Nicholas Castle; Todd P Semla; Chester B Good; Michael J Fine; Maurice Dysken; Joseph T Hanlon Journal: Med Care Date: 2012-11 Impact factor: 2.983
Authors: Nandita Kachru; Holly M Holmes; Michael L Johnson; Hua Chen; Rajender R Aparasu Journal: Curr Med Res Opin Date: 2021-05-13 Impact factor: 2.705